Advancements in 3D in vitro Cell Culture Systems: Enhancing Drug Pharmacokinetics and Toxicity Assessment in Pharmaceutical Development

The development and screening of pharmaceuticals encounter significant predictive inaccuracies when transitioning from animal models to human trials, primarily due to interspecies differences in drug metabolism and effects. Traditional 2D and animal models, although fundamental in early drug development stages, often do not accurately reflect human physiological responses, leading to high attrition rates in clinical phases. This review highlights the emerging role of three dimensional (3D) in vitro models, including organoids and tissue chips, as more predictive and ethically favorable alternatives. These models mimic human physiological and pathophysiological conditions more closely, providing an enhanced platform for drug pharmacokinetics and toxicity assessment. Although there are some disadvantages, innovations in scaffold-based and scaffold-free 3D cultures, bioprinting techniques, and organ-on-chip technologies not only address the limitations of traditional models but also offer profound insights into complex tissue dynamics and drug behaviors. This paper discusses the significant advances in 3D in vitro technologies that promise to refine predictive accuracy, reduce reliance on animal testing, and streamline the pharmaceutical development pipeline.